189 related articles for article (PubMed ID: 30944862)
21. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway.
van Montfort T; van der Sluis R; Darcis G; Beaty D; Groen K; Pasternak AO; Pollakis G; Vink M; Westerhout EM; Hamdi M; Bakker M; van der Putten B; Jurriaans S; Prins JH; Jeeninga R; Thomas AAM; Speijer D; Berkhout B
EBioMedicine; 2019 Apr; 42():97-108. PubMed ID: 30824386
[TBL] [Abstract][Full Text] [Related]
23. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4
Kulpa DA; Talla A; Brehm JH; Ribeiro SP; Yuan S; Bebin-Blackwell AG; Miller M; Barnard R; Deeks SG; Hazuda D; Chomont N; Sékaly RP
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578289
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Latent Reservoir for HIV-1.
Sengupta S; Siliciano RF
Immunity; 2018 May; 48(5):872-895. PubMed ID: 29768175
[TBL] [Abstract][Full Text] [Related]
25. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Cillo AR; Sobolewski MD; Bosch RJ; Fyne E; Piatak M; Coffin JM; Mellors JW
Proc Natl Acad Sci U S A; 2014 May; 111(19):7078-83. PubMed ID: 24706775
[TBL] [Abstract][Full Text] [Related]
26. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
28. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
29. The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.
Washizaki A; Murata M; Seki Y; Kikumori M; Tang Y; Tan W; Wardani NP; Irie K; Akari H
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696466
[TBL] [Abstract][Full Text] [Related]
30. Low-Level Ionizing Radiation Induces Selective Killing of HIV-1-Infected Cells with Reversal of Cytokine Induction Using mTOR Inhibitors.
Pinto DO; DeMarino C; Vo TT; Cowen M; Kim Y; Pleet ML; Barclay RA; Noren Hooten N; Evans MK; Heredia A; Batrakova EV; Iordanskiy S; Kashanchi F
Viruses; 2020 Aug; 12(8):. PubMed ID: 32823598
[TBL] [Abstract][Full Text] [Related]
31. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
32. New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.
Bricker KM; Chahroudi A; Mavigner M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452425
[TBL] [Abstract][Full Text] [Related]
33. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
34. Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA.
Taylor JP; Armitage LH; Aldridge DL; Cash MN; Wallet MA
Biol Open; 2020 Dec; 9(12):. PubMed ID: 33234703
[TBL] [Abstract][Full Text] [Related]
35. Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors That Potently Reactivate Latent HIV.
Curreli F; Ahmed S; Victor SMB; Debnath AK
Viruses; 2020 Jun; 12(6):. PubMed ID: 32503121
[TBL] [Abstract][Full Text] [Related]
36. Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells.
Boucau J; Das J; Joshi N; Le Gall S
PLoS Pathog; 2020 Mar; 16(3):e1008442. PubMed ID: 32196533
[TBL] [Abstract][Full Text] [Related]
37. HIV latency reversal agents: A potential path for functional cure?
Lopes JR; Chiba DE; Dos Santos JL
Eur J Med Chem; 2021 Mar; 213():113213. PubMed ID: 33540228
[TBL] [Abstract][Full Text] [Related]
38. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
39. T cell toxicity of HIV latency reversing agents.
Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
[TBL] [Abstract][Full Text] [Related]
40. Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes.
Tang X; Lu H; Dooner M; Chapman S; Quesenberry PJ; Ramratnam B
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
